Loading stock data…
Genmab A/S (GMAB)
$28.87-0.30 (-1.03%)
Market ClosedLast close Jul 24
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Genmab A/S in the Healthcare sector is trading at $28.87 with a market capitalization of $14.8B. Wall Street consensus targets $37.96 (10 analysts), implying a +31.5% move over the next 12 months. The stock is currently 19% below its 52-week high of $35.43, remaining 1.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +31.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $896.00M↓ | $1.06B↑ | $1.02B↑ | $925.00M↑ | $715.00M |
| Gross Profit | $831.00M↓ | $977.00M↑ | $964.00M↑ | $868.00M↑ | $673.00M |
| Operating Income | $225.00M↓ | $243.00M↓ | $459.00M↑ | $360.00M↑ | $188.00M |
| Net Income | $53.00M↑ | $31.00M↓ | $401.00M↑ | $336.00M↑ | $195.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diff...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$14.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.45%
Volume
Today's trading volume
1.67M
Recent News
AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback
Genmab and AbbVie (ABBV) recently clarified that the U.S. portion of the Phase 3 EPCORE DLBCL-1 trial for epcoritamab did not meet its overall survival primary endpoint, raising fresh questions about the drug's long term commercial potential. See our latest analysis for AbbVie. Against this backdrop, AbbVie’s share price has had a strong run, with a 30-day share price return of 10.42% and a 90-day share price return of 30.52%. Its 1-year total shareholder return of 40.53% highlights momentum...
CoreWeave upgraded, IBM initiated: Wall Street's top analyst calls
CoreWeave upgraded, IBM initiated: Wall Street's top analyst calls
Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks on our list. TheFly reported on July 2 that H.C. Wainwright analyst Raghuram Selvaraju increased the price target on GMAB to $40 from $38 while reaffirming a Buy rating on the shares. […]
Exchange-Traded Funds Lower, Equity Futures Mixed Amid Caution Over Chip Sector Outlook
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1%, and the actively t
Health Care Roundup: Market Talk
Find insight on AstraZeneca, AbbVie, Genmab and more in the latest Market Talks covering Health Care.